Tasso Inc., a pioneer in clinical-grade, at-home, self-sampling blood collection, today announced it has completed an oversubscribed $17 million Series A financing round. The company will use the proceeds to scale manufacturing and operations to meet the increased demand for its line of innovative Tasso OnDemand devices, which enable people to collect their own blood using a virtually painless process from anywhere at any time. These fast and easy-to-use products are being adopted by leading academic medical institutions, government agencies, comprehensive cancer centers, and pharmaceutical organizations around the world.

Tasso, Inc. has completed a $6.1 million round of financing led by Vertical Venture Partners (“VVP”), with participation from Techstars and Cedars-Sinai. This new funding will help Tasso scale its first product Tasso OnDemand, which enables at-home self-collection of blood samples, and grow the team to support significant commercial interest.

Tasso, Inc. (Tasso), Ceres Nanosciences (Ceres), George Mason University (Mason), and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) today announced the commencement of an $11.7 million program, funded by the Defense Threat Reduction Agency (DTRA), to develop a reliable, safe, and simple universal surveillance platform for infectious disease outbreaks.

Tasso, Inc., a medtech start-up developing the HemoLink™, a small disposable device to simplify blood sampling, has secured an additional $2.9M in grant funding to advance its HemoLink technology with its development partner GenTegra LLC.

Tasso, Inc., a medtech start-up developing a wearable blood draw device, has secured $2.3M in grant funding for its HemoLink­™ technology.